Table 2.
Top-ranked pathway terms enriched by genes in each module and group.
| Groups | Module | EMT/VM+ cancer driver gene/whole gene (%) | Biological term | P-value | Genes |
|---|---|---|---|---|---|
| Nevi*-Primary (NP) | Lightcyan | 558/3965 (14.1) | Cell cycle | 0.00047 | CCNA2;PTTG1;E2F1;PKMYT1;CDC25B |
| Progesterone-mediated oocyte maturation | 0.03363 | CCNA2;PKMYT1;CDC25B | |||
| Oocyte meiosis | 0.04279 | PTTG1;PKMYT1;AURKA | |||
| Nevi-Metastasis (NM) | Magenta | 862/6543 (13.2) | Protein digestion and absorption | 0.00022 | COL15A1;COL1A2;COL5A1;COL14A1;COL6A2 |
| ECM-receptor interaction | 0.01304 | COMP;COL1A2;COL6A2;CD36 | |||
| Primary-Metastasis (PM) | Brown | 33/139 (23.7) | Cytokine-cytokine receptor interaction | 0.00006 | CX3CR1;IL4R;IL1R2;IL18;CSF2RB;TNF;IL18RAP;CXCR2;CCL19;CCL18;IL7R;IL18R1 |
| NF-kappa B signaling pathway | 0.00546 | LCK;BLNK;CCL19;TNF;BIRC3 | |||
| T cell receptor signaling pathway | 0.00021 | ITK;LCK;MAP3K8;ICOS;TNF;RASGRP1;CD3D;MAPK13 | |||
| Hematopoietic cell lineage | 0.00007 | CD2;IL4R;IL1R2;CD24;IL7R;CD1C;TNF;CD3D |
⁎
Nevi refers to patients if they diagnosed with any abnormal, congenital formation or mark on the skin or neighbouring mucosa that does not show neoplastic growth.
Abbreviations: VM, vascular mimicry; EMT, epithelial to mesenchymal transition.